(NYSE: RDY) Dr Reddys Laboratories's forecast annual revenue growth rate of 5.12% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 5.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.88%.
Dr Reddys Laboratories's revenue in 2024 is $3,350,504,080.On average, 3 Wall Street analysts forecast RDY's revenue for 2025 to be $3,132,026,289,611, with the lowest RDY revenue forecast at $3,056,694,497,051, and the highest RDY revenue forecast at $3,193,485,475,171. On average, 3 Wall Street analysts forecast RDY's revenue for 2026 to be $3,291,808,161,151, with the lowest RDY revenue forecast at $3,163,825,187,476, and the highest RDY revenue forecast at $3,509,430,930,062.
In 2027, RDY is forecast to generate $3,205,240,324,285 in revenue, with the lowest revenue forecast at $3,054,951,246,171 and the highest revenue forecast at $3,396,987,077,864.